Compare Petróleo Brasileiro SA (PBR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Smith & Nephew plc — how do they compare? Petróleo Brasileiro SA trades at $24.65 (market cap $151.94B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Petróleo Brasileiro SA is far larger — about 13.7× Smith & Nephew plc's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Smith & Nephew plc for 120 Days on average.
| PBR | SNN | |
|---|---|---|
Market Cap | $151.94B | $11.10B |
Volume | 30,240,092 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $24.69 | $37.17 |
52-Week Low | $11.54 | $26.42 |
Typical Hold Time | 25 Days | 120 Days |
Enterprise Value | $212.36B | $14.13B |
Dividend Yield | 6.79% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $23.99, up 0.8% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 6.24 and net income margin of 24.52%. Recent news highlights a new oil discovery off Amapa and the deployment of the P-80 platform, supporting production growth. Cash flow from operations remains robust at $36.05 billion for 2025, though 2026 projections show a net cash outflow.
The outlook is positive given low valuations, high profitability, and strategic expansions, but risks include volatile oil prices and political influence in Brazil. Analysts are generally bullish with a 50% buy rating and a consensus price target of $22.33, slightly below the current price, indicating potential near-term consolidation.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
